PAD was delineated in seven trials (2, 2, 2, and 1 with canagliflozin, dapagliflozin, ertugliflozin, and tofogliflozin, respectively) for an amount of 216 events with SGLT2-is versus 193 events with comparators, thus resulting in a pooled RRMH of 1.04 [0.67–1.61] (Figure 4). This evidence concerns the gene SLC5A2 and peripheral arterial disease.